Key Takeaways:
- Small-molecule GLP-1 drugs like orforglipron penetrate deep into the brain's central amygdala to suppress pleasure-based eating
- This mechanism is different from injectable GLP-1s and could lead to treatments for substance use disorders
- The discovery explains why oral GLP-1 pills may work differently than weekly injections for weight loss
A new study funded by the National Institutes of Health has revealed that small-molecule GLP-1 drugs — the active ingredients in new oral weight loss pills — work by penetrating deeper into the brain than scientists previously thought possible. The research found that these emerging drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain.
In the study, researchers at the University of Virginia specifically investigated small-molecule GLP-1 receptor agonists, such as the Food and Drug Administration (FDA)-approved orforglipron, which powers Eli Lilly's Foundayo pill that launched this spring.
How Oral GLP-1s Work Differently Than Injections
Previous research has extensively explored the effects of larger peptide GLP-1s, such as semaglutide, in the brain, finding that they suppress hunger-driven eating by engaging networks in the hypothalamus and hindbrain. But this new research reveals that oral versions work through an entirely different pathway.
The team administered orforglipron or another small-molecule drug, danuglipron, and identified brain regions where they induced activity. While the GLP-1s affected familiar territory, they also triggered activity in the central amygdala, a region associated with desire that is deeper in the brain than scientists previously thought GLP-1s could directly reach.
Further experiments showed that, once activated, the central amygdala reduced dopamine release into key hubs of the brain's reward circuitry during hedonic feeding. This represents a fundamentally different approach to weight loss than the hunger-suppressing effects of injectable medications like semaglutide or tirzepatide.
Targeting Pleasure-Based Eating Patterns
"We've known that GLP-1 drugs suppress feeding behavior driven by energy demand. Now it seems oral small-molecule GLP-1s also dial back eating for pleasure by engaging a brain reward circuit," said co-corresponding author Ali Guler, Ph.D, a professor of biology at the University of Virginia.
This discovery helps explain why some people find significant success with oral GLP-1 medications beyond traditional appetite suppression. The drugs appear to directly target the brain circuits that drive us to eat for pleasure rather than hunger — addressing what many describe as "food noise" or constant food cravings.
The central amygdala has long been recognized as a key player in emotional responses and reward processing. When you reach for comfort food after a stressful day or find yourself unable to stop eating despite feeling full, this brain region is often involved. The fact that oral GLP-1s can directly influence this area suggests they may be particularly effective for people whose weight challenges are rooted in emotional or stress-driven eating patterns.
Potential for Addiction Treatment
This newly charted pathway — separate from previously described mechanisms that broadly affect appetite — could be an avenue by which GLP-1s treat other dysfunctions in reward processing, such as substance use disorder.
According to scientists, the natural next question is whether these next-generation GLP-1s can also tone down cravings for things other than food. In follow-up studies they hope to dive into their effects on substance use disorder specifically.
This research adds scientific backing to anecdotal reports from people using GLP-1 medications who have noticed reduced cravings for alcohol, nicotine, and other substances. The discovery that oral GLP-1s can directly target the brain's reward center suggests these effects aren't coincidental but rather a direct result of how these medications interact with our neural reward pathways.
Understanding the Oral vs Injectable Difference
Until now, scientists have had a much less firm grasp on how small-molecule GLP-1 drugs work. This research provides the first clear evidence that pills like Foundayo and the upcoming oral semaglutide work through mechanisms distinct from weekly injections.
The findings suggest that people who switch from injectable GLP-1s to oral versions may experience different effects. While many telehealth providers often frame the choice between pills and injections as a matter of convenience, this research indicates the medications may actually target different aspects of overeating.
Injectable GLP-1s primarily work by slowing gastric emptying and affecting hormone levels that signal fullness to your brain. This makes you feel satisfied with smaller portions and reduces the physical sensation of hunger. Oral GLP-1s, according to this research, add another layer by directly affecting the reward circuits that drive cravings and pleasure-seeking food behaviors.
This distinction could be particularly important for people who struggle with specific eating patterns. If your main challenge is portion control and feeling full, injectable medications might be more effective. If you find yourself constantly thinking about food or eating in response to emotions rather than hunger, oral medications might offer additional benefits.
What This Means for You
If you're considering GLP-1 treatment or currently using an injectable medication, this research provides valuable insights into how oral options might work differently for your specific situation. The discovery that oral GLP-1s target pleasure-based eating could make them particularly effective for people whose weight challenges stem from emotional eating, stress eating, or food addiction patterns.
For people who haven't found complete success with injectable GLP-1s due to persistent food cravings despite appetite suppression, oral medications might offer a complementary approach by directly targeting the brain's reward system. You can find a clinic near you that offers both injectable and oral GLP-1 options to discuss which approach might work best for your specific patterns of eating and weight challenges.
When talking with providers, consider sharing details about your eating patterns — whether you tend to eat when stressed, struggle with specific food cravings, or find yourself eating despite not feeling hungry. This information can help determine whether the reward-targeting effects of oral GLP-1s might be particularly beneficial for your situation.
Sources
- Oral small-molecule GLP-1 drugs penetrate deep into the brain to suppress cravings - National Institutes of Health press release, May 14, 2026